N
Nabil Dib
Researcher at University of California, San Diego
Publications - 69
Citations - 4816
Nabil Dib is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Myocardial infarction & Transplantation. The author has an hindex of 23, co-authored 60 publications receiving 4362 citations. Previous affiliations of Nabil Dib include Beth Israel Deaconess Medical Center & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction
Joshua M. Hare,Jay H. Traverse,Timothy D. Henry,Nabil Dib,Robert K. Strumpf,Steven P. Schulman,Gary Gerstenblith,Anthony N. DeMaria,Ali E. Denktas,Roger Gammon,James B. Hermiller,Mark A. Reisman,Gary L. Schaer,Warren Sherman +13 more
TL;DR: This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients and indicates intravenousAllogeneic hMSCs are safe in patients after acute MI.
Journal ArticleDOI
Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction
Sonya B. Seif-Naraghi,Jennifer Singelyn,Michael A. Salvatore,Kent G. Osborn,Jean J. Wang,Unatti Sampat,Oi Ling Kwan,G. Monet Strachan,Jonathan Wong,Pamela J. Schup-Magoffin,Rebecca L. Braden,Kendra Bartels,Jessica A. DeQuach,Mark C. Preul,Adam Kinsey,Anthony N. DeMaria,Nabil Dib,Karen L. Christman +17 more
TL;DR: Data in a large animal show that the myocardial ECM–derived material not only improves functional outcome after a heart attack but also is safe and nontoxic, thus making the material ready to move forward toward clinical tests in people.
Journal ArticleDOI
Safety and Feasibility of Autologous Myoblast Transplantation in Patients With Ischemic Cardiomyopathy Four-Year Follow-Up
Nabil Dib,Robert E. Michler,Francis D. Pagani,Susan Wright,Dean J. Kereiakes,Rose Lengerich,Philip F. Binkley,Diane Buchele,Inder S. Anand,Cory Swingen,Marcelo F. Di Carli,James D. Thomas,Wael A. Jaber,Shaun R. Opie,Ann Campbell,Patrick M. McCarthy,Michael Yeager,Vasken Dilsizian,Bartley P. Griffith,Ronald L. Korn,Steven K. Kreuger,Marwan Ghazoul,W. Robb MacLellan,Gregg C. Fonarow,Howard J. Eisen,Jonathan Dinsmore,Edward B. Diethrich +26 more
TL;DR: These results demonstrate the survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality offers a potential therapeutic treatment for end-stage heart disease.
Journal ArticleDOI
Catheter-Deliverable Hydrogel Derived From Decellularized Ventricular Extracellular Matrix Increases Endogenous Cardiomyocytes and Preserves Cardiac Function Post-Myocardial Infarction
Jennifer Singelyn,Priya Sundaramurthy,Todd D. Johnson,Pamela J. Schup-Magoffin,Diane P. Hu,Denver M. Faulk,Jean Wang,Kristine M. Mayle,Kendra Bartels,Michael A. Salvatore,Adam Kinsey,Anthony N. DeMaria,Nabil Dib,Karen L. Christman +13 more
TL;DR: This is the first in situ gelling material to be delivered via transendocardial injection in a large animal model, a critical step towards the translation of injectable materials for treating MI in humans.
Journal ArticleDOI
Rheolytic Thrombectomy With Percutaneous Coronary Intervention for Infarct Size Reduction in Acute Myocardial Infarction: 30-Day Results From a Multicenter Randomized Study
Arshad Ali,David A. Cox,Nabil Dib,Bruce R. Brodie,Daniel S. Berman,Navin Gupta,Kevin F. Browne,Robert S Iwaoka,Michael Azrin,Dwight D. Stapleton,Cindy M. Setum,Jeffrey J. Popma,Aimi Investigators +12 more
TL;DR: Despite effective thrombus removal, RT with primary PCI did not reduce infarct size or improve TIMI flow grade, TMP blush, ST-segment resolution, or 30-day MACE.